登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CD200 R1】

CD200 R1信息

英文名称:Cell surface glycoprotein CD200 receptor 1
中文名称:CD200细胞表面糖蛋白受体1
靶点别称:Cell surface glycoprotein OX2 receptor 1,CD200 cell surface glycoprotein receptor,CD200R
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

Licensing 项目合作

项目名称 药物类型 治疗领域 适应症 阶段 权益地区
高选择性OX1R/OX2R双靶点抑制剂 小分子 神经系统疾病 失眠 临床I期 全球

CD200 R1产品列表

ACRO质量管理体系
 
评论(1)
CR2-H52H6|Human CD200 R1 / CRTR2 Protein, His Tag
  1. 158XXXXXXX7
  2. 0人赞
  3. 本次实验用的蛋白是CR2-H52H6的人源蛋白,实验目的是验证抗原抗体的识别、结合效果,实验结果还是很好的,该蛋白非常有活力,结合也很好。
  4. 2024-08-06
 

CD200 R1 分子别名

CD200R,CRTR2,MOX2R,OX2R

CD200 R1 分子背景

Cell surface glycoprotein CD200 receptor 1 is a protein that in humans is encoded by the CD200R1 gene.This gene encodes a receptor for the OX-2 membrane glycoprotein. Both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains. This receptor is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal. CD200 and its receptor CD200R are both type-1 membrane glycoproteins, which are members of the immunoglobulin superfamily (IgSF). Besides the inhibitory effect on macrophages, CD200/CD200R also play an important role in regulating the regulatory T cells, allergicreaction, autoimmune diseases, allograft, neurological diseases and other autoimmune-related diseases.The interaction between CD200, which is mainly present in neurons but also in astrocytes, and CD200R1, which is mainly present in microglia, is one of the mechanisms involved in keeping the microglial proinflammatory phenotype under control in physiological conditions. Alterations in the expression of CD200 and CD200R1 have been described in neurodegenerative diseases, but little is known about the mechanism of regulation of these proteins under physiological or pathological conditions.

CD200 R1 前沿进展

CD200 R1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
P-006 P-006; 23ME-610; 23ME-00610 临床二期 23andme Inc 实体瘤, 肾细胞癌, 小细胞肺癌, 卵巢上皮癌, 神经内分泌瘤, 腹膜癌, 输卵管癌 详情
Ucenprubart LY-3454738 临床二期 礼来制药 慢性荨麻疹, 特应性皮炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定